Alligator Bioscience Valuation
Is ATORX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Share Price vs Fair Value
What is the Fair Price of ATORX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ATORX?
Key metric:
| What is ATORX's PS Ratio? | |
|---|---|
| PS Ratio | 0.5x |
| Sales | SEK 57.72m |
| Market Cap | SEK 30.63m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.2x |
| Enterprise Value/EBITDA | -0.05x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does ATORX's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 9x | ||
GEAN Genetic Analysis | 1.1x | n/a | NOK 22.2m |
DEX Dextech Medical | 17.1x | n/a | SEK 73.9m |
PROGEN Prostatype Genomics | 15.1x | n/a | SEK 62.2m |
LPGO Lipigon Pharmaceuticals | 2.8x | 127.1% | SEK 25.2m |
ATORX Alligator Bioscience | 0.5x | 10.9% | SEK 30.6m |
Price to Sales Ratio vs Industry
How does ATORX's PS Ratio compare vs other companies in the SE Biotechs Industry?
| 9 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| Industry Avg. | 14.7x | 19.8% | |
ATORX Alligator Bioscience | 0.5x | 10.9% | US$2.76m |
XBRANE Xbrane Biopharma | 1.3x | 58.0% | US$24.06m |
SPRINT Sprint Bioscience | 1.8x | 27.6% | US$9.85m |
| 9 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
| Industry Avg. | 14.7x | 30.5% | |
ATORX Alligator Bioscience | 0.5x | 53.5% | US$2.76m |
Price to Sales Ratio vs Fair Ratio
What is ATORX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.5x |
| Fair PS Ratio | 0.1x |
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Discover undervalued companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/02 06:22 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Alligator Bioscience AB (publ) is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ingrid Gafanhão | Kempen & Co. NV |
| Carl Ramanius | Redeye |